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Summary: Severe tissue carnitine deficiency impairs fatty acid oxidation. In explanted hearts from patients
with end stage heart failure a 57% carnitine decrease was found in comparison with healthy donor hearts
(p < 0.05). The reduction of myocardial carnitine levels affected all areas of the explanted hearts to a
comparable extent. Carnitine decreases in patients with dilated cardiomyopathy or coronary artery disease
were similar.
Endomyocardial biopsies from patients with less severe heart failure due to cardiomyopathy (n = 28) or other
myocardial diseases (n = 8) showed a 42% decrease of total myocardial carnitine (in nmol/mg non-collagen
protein) in comparison with biopsies from patients with normal cardiac function (controls) (heart failure: 5.7,
confidence interval 4.2 — 7.0; controls 9.3, confidence interval 7.6 — 12.0, p < 0.005). Free myocardial carnitine
in heart failure was also different from controls (heart failure: 4.2, confidence interval 3.7 — 5.3; controls 10.3,
confidence interval 7.5 — 12.2, p < 0.001). The decrease of free and total myocardial carnitine was comparable
in dilated cardiomyopathy and heart failure due to other diseases. Alterations in myocardial carnitine content
represent therefore non-specific biochemical markers in heart failure with yet unknown consequences for
myocardial function.
Introduction , .
 f j ^ uassessed in end-stage heart failure and the homogene-
In dilated cardiomyopathy, primary metabolic defects ity and distribution of the changes can be studied. In
probably cause an impairment of cardiac function. In addition, micromethods as well as adequate reference
heart failure due to coronary, valvular or hypertensive systems have been developed that enable the investi-
heart disease an abnormal haemodynamic burden gation of endomyocardial biopsies from patients with
leads to hypertrophy and secondary metabolic less severe stages of heart failure (2). Thus, it is now
changes (1). Since the lack of adequate amounts of possible to identify metabolic defects in end-stage
tissue for biochemical studies has always limited the heart failure and to search for corresponding changes
investigation of myocardial metabolism in human in endomyocardial biopsies from patients in the early
heart disease, little information on these metabolic stages of heart failure.
defects is available. „ ., . - . . - . „ -
ratty acid oxidation is the major energy source 01 the
However, as myocardial tissue can now be obtained heart (3). Carnitine plays an essential role in mito-
at cardiac transplantation, metabolic defects can be chondrial fatty acid uptake, and patients with severe
carnitine deficiency are almost unable to oxidize lipids
') This work was supported by the DFG, grant Fl 165/1-1 and (4> 5)· TheY Present with severe HPid accumulation in
Re 662/1-2. most tissues, with muscle weakness and, often, with
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clinical signs of dilated cardiomyopathy (6, 7). Since
there are indicators that myocardial fatty acid oxi-
dation may be disturbed in patients with dilated car-
diomyopathy, we decided to study the myocardial
carnitine content as a parameter for the capacity to
oxidize lipids in patients with heart failure (8).
In the first part of the study, carnitine was measured
in explanted hearts to evaluate whether a carnitine
loss occurs in heart failure and which areas of the
heart are involved. Subsequently, measurements were
undertaken on endomyocardial biopsies to determine
whether patients who have not yet reached end-stage
heart failure have defects in carnitine metabolism.
Methods
Studies in explanted hearts
In a first series of experiments myocardial carnitine content
was measured in the explanted hearts of 66 patients who had
undergone heart transplantation because of end-stage heart
failure. Thirty nine of 66 patients had dilated cardiomyopathy
and 27 had coronary artery disease. Both patient groups had a
comparable reduction in left ventricular ejection fraction (di-
lated cardiomyopathy: 21%, coronary artery disease: 22%),
cardiac index (dilated cardiomyopathy: 2.1 1/min · m2, coronary
artery disease: 2.3 1/min · m2) and left ventricular end-diastolic
pressure (dilated cardiomyopathy: 22 mmHg, coronary artery
disease: 22 mmHg).
Samples for the measurement of total carnitine were taken in
all patients from the base of the left ventricle and from the free
waU of the right ventricle. In addition, samples from the middle
(41/65) and from the apex of the left ventricle (44/65), from the
septum interventriculare (35/66), and from the right atrium
(46/66) were studied. In 25 patients, samples from 6 areas of
the heart (base, middle, and apex of the left ventricle, septum
interventriculare, right ventricle, and right atrium) were taken.
These samples were used to study the regional distribution of
total carnitine in failing hearts. All samples were taken in the
operating room, less than 15 min after explantation of the
heart, immediately frozen on dry ice and stored at — 70 °C until
analysis.
Free carnitine was not determined in the explanted hearts
because the time between explantation and freezing was be-
tween 15 and 30 min. This does not influence total carnitine
levels; but carnitine esters may accumulate in this period of
global ischaemia and thus, the relative amounts of free and
total carnitine will be altered (9).
Left ventricular biopsies from healthy donor hearts (n = 10)
and right atrial biopsies obtained at aortocoronary bypass
surgery from patients without heart failure (n =14) were used
as controls.
Tab. 1. Haemodynamic parameters in patients with dilated cardiomyopathy (la), with heart failure due to other causes (Ib) and
in normal controls (Ic).
a) Heart failure due to dilated cardiomyopathy
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Mean
SE
Left ventricular
end-diastolic
pressure
(mm Hg)
40
12
8
30
18
25
10
9
9
12
21
24
16
23
35
4
20
12
4
22
26
20
30
35
28
6
26
13
19
2
Right ventricu-
lar ejection
fraction(%>
31
41
16
59
28
41
49
50
45
49
43
60
27
34
50
_
20
40
53
28
54
41
15
34
41
29
44
39
2
Left ventricular
ejection
fraction
(%)
31
35
40
12
33
16
39
33
43
44
53
37
44
19
19
33
15
20
45
43
30
30
19
12
26
41
20
34
31
2
Left ventricular
end-diastolic
volume index
(ml/m2)
224
212
162
300
279
257
160
156
146
156
180
167
178
328
245
141
178
351
125
153
200
157
140
242
180
131
247
194
200
13
Left ventricular
end-systolic
volume index
(ml/m2)
156
136
97
262
187
216
98
105
84
88
84
105
100
266
199
95
137
200
68
87
139
110
114
212
132
77
197
128
193
11
Cardiac
index
(ml/m2 χ min)
2.9
4.5
3.8
4.8
4.1
2.9
3.8
3.8
2.8
2.3
5.6
4.6
3.6
2.1
3.3
2.9
2.1
2.1
3.1
3.4
2.7
3.1
3.6
3.3
2.6
3.9
3.1
3.7
3
0.2
— not determined
J. Clin. Chem. Clin. Biochem. / Vol. 28, 1990 / No. 9
Regitz et al.: Metabolic alterations in heart failure: myocardial carnitine decrease 613
b) Heart failure of different origin
Patient
1
2
3
4
5
6
7
8
Mean
SE
Left ventricular
end-diastolic
pressure
(mm Hg)
8
15
20
8
14
19
18
20
16
2
Right ventricu-
lar ejection
fraction
(%)
39
47
—
55
—
66
55
52
2
Left ventricular
ejection
fraction
(%)
50
24
31
39
28
25
26
51
34
4
Left ventricular
end-diastolic
volume index
(ml/m2)
140
219
318
158
236
179
303
131
211
26
Left ventricular
end-systolic
volume index
(ml/m2)
70
167
220
97
107
134
226
64
136
22
Cardiac
index
(ml/m2 χ min)
4.2
3.9
4.4
2.2
3.6
3.1
5.0
6.0
4
0.4
— not determined
c) Controls
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
Mean
SE
Left ventricular
end-diastolic
pressure
(mm Hg)
11
17
9
24
10
10
11
20
9
7
12
6
13
12
1
Right ventricu-
lar ejection
fraction
(%)
49
54
60
62
—
—
56
—56
60
58
—
57
58
2
Left ventricular
ejection
fraction
(%)
64
67
67
59
62
67
73
63
63
69
72
57
64
65
1
Left ventricular
end-diastolic
volume index
(ml/m2)
156
111
112
126
75
129
85
109
90
83
131
160
107
111
9
Left ventricular
end-systolic
volume index
(ml/m2)
57
37
36
52
28
42
23
41
33
25
36
69
39
39
3
Cardiac
index
(ml/m2)
4.0
2.8
3.9
5.6
3.1
2.3
3.5
5.1
5.4
3.6
3.8
4.8
5.0
4
0.3
— not determined
Studies in endomyocardial biopsies
A second part of the study comprised 28 adults with dilated
cardiomyopathy, 8 with heart failure of other origins, and 13
controls without heart disease. After an overnight fast, all
subjects underwent complete non-invasive and invasive diag-
nostic studies including right and left sided heart catheteriza-
tion, determination of cardiac index by thermodilution tech-
nique, biplane right and left ventricular angiography, coronary
angiography, and right ventricular endomyocardial biopsy. The
diagnosis of dilated cardiomyopathy was based on a left ven-
tricular ejection fraction of < 55% after exclusion of primary
coronary, valvular, hypertensive, or pulmonary heart disease
and myocarditis (tab. la). Of the 8 patients whose heart failure
was attributed to causes other than dilated cardiomyopathy, 3
had predominantly coronary artery disease, 3 had valvular, and
2 had hypertensive heart disease (tab. Ib).
The 13 controls were subjects in whom invasive diagnostic
examination was undertaken for suspected coronary artery
disease and in whom normal coronary arteries together with a
normal left ventricular ejection fraction (> 55%), without val-
vular, hypertensive or pulmonary heart disease, were found
(tab. Ic).
Total myocardial carnitine was measured in biopsies from all
patients and controls. Biopsies were frozen on dry ice less than
20 s after sampling. This short interval should not allow sig-
nificant accumulation of carnitine esters. Therefore, if possible
(depending on sample size), free myocardial carnitine was de-
termined in the same biopsies (22 patients and 11 controls) and
the ratio free/total carnitine was calculated separatedly for every
sample.
Biochemical determinations
Myocardial carnitine was measured using a radio-enzymatic
standard assay and microassay, specially adapted for endo-
myocardial biopsy, as published recently (2, 10). Total carnitine
was measured directly after alkaline hydrolysis of plasma or
tissue homogenate. Free carnitine was determined after acid
extraction and neutralization of the sample (9).
Non-collagen protein was used as a reference system. Collagen
protein was first extracted from the diluted tissue homogenate
(11), followed by a conventional protein determination (12).
Based on our previous studies, the intra-assay coefficients of
variation for total and free carnitine in concentrations from 50
to 500 pmol are 4% and 9%, respectively. The recovery rate
for externally added free and acetyl-carnitine in amounts from
25 to 100 nmol/sample are 95 + 8% (free) and 92 ± 14% (ace-
tyl-carnitine). The coefficient of variance for determinations
from several biopsy-sized samples from the same heart is 13%,
with a 95% confidence interval of 1.9 nmol carnitine per mil-
ligram non-collagen protein (2). Micro- and regular assay yield
identical results.
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Statistics
Data are given as median and confidence interval. The U-test
of Wilcoxon, Mann & Whitney was used to compare groups,
and values of p < 0.05 were considered significant.
To compare the carnitine content of different areas of the
explanted hearts, independent of the absolute levels, samples
were ranked from lowest (1) to highest (6) carnitine content in
each of the 25 patients where carnitine levels were determined
in 6 areas. The average rank for the samples at each location
was then calculated for each area.
For the patients that were not yet in end-stage heart failure,
regression analysis was done between free myocardial carnitine
(x, = independent variable) and left ventricular ejection frac-
tion, (y, = dependent variable) using y = a + b/x as a non-
linear curve fitting model.
Results
Myocardial carnitine content in end-stage
heart failure —
Measurements in explanted hearts
Sixty six patients with heart failure due to dilated
cardiomyopathy or coronary artery disease had sig-
nificantly reduced myocardial carnitine concentra-
tions in all areas of the explanted hearts, compared
with control values. Carnitine levels (in nmol/mg non-
collagen protein) in patients were: left ventricular base
5.7, left ventricular mid 6.2, left ventricular apex 5.8,
septum 5.3, right ventricle 5.8, right atrium 4.8. Con-
trol values were 13.3, confidence interval 9.7 — 19.4 in
the left ventricle and 11.7, confidence interval 9.8 —
14.1 in the right atrium (p < 0.05 for all areas). Pa-
tients with dilated cardiomyopathy and coronary ar-
tery disease showed no differences in myocardial car-
nitine content. In both groups the decrease of carni-
tine affected all areas of the heart (fig. 1).
Right Left ventricle Right Septum Right
ventricle atrium Base Mid Apex ventricle atrui  ium
n=10 n=14 n=66 n=41 n=44 n=66 n=35 n=46
Fig. 1. Myocardial total carnitine content in patients with heart
failure disease and in controls. Median and confidence
interval.
Eä Controls
Dilated cardiomyopathy
Coronary artery disease
* < 0.05 vs controls (right atrium + left ventricle)
The distribution of carnitine independent of the ab-
solute values was obtained by an analysis by rank
(fig. 2). Highest carnitine concentrations were found
at the base of the left ventricle, followed by the mid
area of the left ventricle with comparable levels in
right ventricle, septum, and left ventricular apex. The
lowest carnitine content was found in the right atrium
(fig-2).
7 ö
R
6 c
5 ö
O)
3 ^
c
2 V
Left ventricle Right Septum Right
Base Mid Apex ventricle atrium
Fig. 2. Average ranks for the carnitine concentrations in each
of 6 areas of the heart (triangles) and absolute carnitine
concentrations (circles) in the corresponding areas.
To compare the carnitine content in different areas of
the explanted hearts, independent of the absolute levels,
samples were ranked from lowest (1) to highest (6)
carnitine content in each of the 25 patients; carnitine
levels were determined in 6 areas. The average rank for
the samples at each location was then calculated for
each area.
Myocardial carnitine content in less severe
stages of heart failure —
Measurements in endomyocardial biopsies
Patients with heart failure showed a significant de-
crease of myocardial carnitine (in nmol/mg non-col-
lagen protein) compared with controls (heart failure:
5.7, confidence interval 4.2 —7.0; controls: 10.3, con-
fidence interval 7.6 — 12.0, p < 0.005). There was a
tendency towards a greater myocardial carnitine de-
crease in patients with left ventricular ejection frac-
tions < 30% (52% carnitine loss) than in patients
with left ventricular ejection fractions 30 — 55% (39%
carnitine loss) (fig. 3a). A comparable decrease of
total myocardial carnitine was found in patients with
heart failure caused by dilated cardiomyopathy and
patients with heart failure of different origins (fig. 3b).
Free myocardial carnitine (in nmol/mg non-collagen
protein) in 22 patients with heart failure was signifi-
cantly reduced compared with 11 normal controls
(heart failure: 4.2, confidence interval 3.7 — 5.3, con-
trols: 10.3, confidence interval 7.5-12.2, p < 0.001).
Differences between patients with left ventricular ejec-
tion fraction < 30% and left ventricular ejection frac-
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Fig. 3. Myocardial total carnitine content in
a) patients with congestive heart failure and left ven-
tricular ejection fraction < 30% or 30 — 55% and
controls. Median and confidence interval.
b) patients with dilated cardiomyopathy, with conges-
tive heart failure due to other diseases and controls.
Median and confidence interval.
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ο
| 60
I s o
Λ ^0
=ϊ
f 30
ω 20
10 ι
3 4 5 6 7 8 9 10 11 12 13
Free carnitine [nmol/mg non-collagen protein]
14
Fig. 5. Results of non-linear regression analysis between free
myocardial carnitine content and left ventricular ejec-
tion fraction demonstrating a non-linear correlation. If
the equation of the curve fitting model is transformed
with Z = I/free carnitine as the new independent vari-
able, a linear correlation coefficient of r = 0.67 is ob-
tained.
Left ventricular ejection fraction =
74.58 - free carnitine
tion 30 — 55% were not significant (fig. 4a). Free
myocardial carnitine did not differ between patients
with heart failure due to dilated cardiomyopathy or
to coronary or valvular disease (fig. 4b). A non-linear
relation was found between free myocardial carnitine
and left ventricular ejection fraction (fig. 5).
The ratio, myocardial free/total carnitine, was 0.81
± 0.05 in the heart failure group and 0.91 + 0.03 in
the control group; the difference was not significant.
p < 0.001 p < 0.005
p < 0.00 2 p<0.001
10 -
6
"E 2
10
Controls Ejection fraction
<30% ^30%
n = 11 n=7 n=15
E 2
it 0 Controls Dilated Other
cardio- diseases
myopathy
n=11 n = 18 n=4
Fig. 4. Myocardial free carnitine content in
a) patients with congestive heart failure and left ven-
tricular ejection fraction < 30% or 30 — 55% and
controls. Median and confidence interval.
b) patients with dilated cardiomyopathy, with heart
failure due to other diseases and controls. Median
and confidence interval.
Discussion
Carnitine, a low molecular weight amino acid deriv-
ative, is essential for the oxidation of fatty acids, the
preferred source of energy for the heart (3,13). Severe
tissue carnitine depletion impairs fatty acid oxidation
and thus leads to cardiac failure (4 — 7). We found a
significant myocardial carnitine decrease in explanted
hearts with end stage heart failure and confirmed a
similar decrease in endomyocardial biopsies from pa-
tients with less severe disease. Studying the same
metabolic alterations first in explanted hearts and
later in endomyocardial biopsies offers several advan-
tages: the range between normal and end stage disease
as well as the reproducibility of measurements and
regional distribution of metabolites can be determined
on large samples and serves as a basis for the inves-
tigation of biopsies.
In the explanted hearts, no differences were found
between carnitine levels in the left ventricle and right
ventricular septum. We and others found significant
correlations between biochemical changes in the right
ventricular septum and functional parameters in the
left ventricle (14, 15). Thus, the septum probably
resembles in its biochemical properties the left ven-
tricle, and biopsies from the right ventricular septum
may be used to estimate the carnitine content in the
left ventricle.
The use of an appropriate reference system is of major
importance for obtaining accurate metabolite levels
in endomyocardial biopsies. The variability between
J. Clin. Chem. Clin. Biochem. / Vol. 28, 1990 / No. 9
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different samples from the same area of the heart is
much more pronounced when wet weight rather than
non-collagen protein is used as a reference system.
Since this variability increases with decreasing sample
size it appears to be optimal to relate metabolite levels
in biopsies to non-collagen protein or to other more
specific reference systems (2).
Patients with heart failure due to dilated cardiomy-
opathy or to other cardiac diseases revealed a com-
parable reduction in myocardial carnitine. Thus, al-
terations in carnitine metabolism apparently represent
metabolic changes associated with heart failure, re-
gardless of its origin (16, 17).
A decrease of myocardial carnitine is not only present
in end stage heart failure but is also found in less
severe disease. Free myocardial carnitine represents
the important part of the carnitine pool that can
actively participate in the transesterification of cyto-
solic fatty acid coenzyme A esters. In our patients,
relatively high ratios of free/total carnitine were
found, possible due to the fact that all patients were
studied in the fasting state. The correlation between
free myocardial carnitine and the left ventricular ejec-
tion fraction suggests an association between the re-
duction in myocardial carnitine levels and the im-
pairment of cardiac function, in spite of a great in-
terindividual variability. Either impaired accumula-
tion of carnitine may reflect the severity of myocardial
damage, or the myocardial carnitine decrease contrib-
utes to the reduction of myocardial function — in
addition to a considerable heterogeneity of myocar-
dial metabolism in heart failure (2,16).
Primary as well as secondary carnitine deficiency syn-
dromes have been described (18 — 20). The patients
affected are mainly characterized by low plasma car-
nitine levels. In contrast, heart failure patients usually
present with high plasma carnitine (15, 17). Reduced
myocardial carnitine in the presence of high plasma
levels may be caused by defects in the synthesis of the
carnitine precursor, butyro-betaine, or defects in the
carrier system, as in diphtheria (21, 22). In addition,
non-specific membrane damage, like that in ischae-
mia, may be involved in the pathogenesis of carnitine
deficiency in heart failure (9).
A possible effect of carnitine supplementation in heart
failure depends on myocardial carnitine levels. Thus,
proper selection of patients, based on tissue carnitine
levels, is required for any therapeutic trials.
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